DGC - SUPPLY OF RITUXIMAB 500 MG 50 ML INJ SOL VIAL - RITUXIMAB 100 MG 10 ML INJ SOL VIAL
About This Opportunity
TranslatedThis tender, issued by DGC, concerns the supply of Rituximab, a monoclonal antibody used in the treatment of certain cancers and autoimmune diseases. Specifically, the procurement covers two presentations of the drug: Rituximab 500 mg in a 50 ml solution for injection in a vial, and Rituximab 100 mg in a 10 ml solution for injection in a vial. The tender outlines the requirements for the provision of these pharmaceutical products, likely including specifications regarding quality, packaging, expiry dates, and delivery timelines. Interested suppliers are expected to meet stringent regulatory standards for pharmaceutical manufacturing and distribution. The scope of the contract will involve ensuring a consistent and reliable supply of Rituximab to meet the needs of the procuring entity, which is presumably a healthcare institution or government health agency. Further details regarding the tender process, including submission deadlines, eligibility criteria, and evaluation methods, would be available in the full tender documentation. This procurement is crucial for maintaining the availability of essential treatment options for patients requiring Rituximab therapy.
This is a supplies contract in the health and medical services and general supplies sectors, with a focus on Pharmaceuticals and General Supplies. Located in Chile, Latin America, this opportunity is open to firms and consortiums.
Published through Chile Mercado Publico, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.
Description
Original language: SpanishThis tender, issued by the Dirección General de Concesiones (DGC) in Chile, seeks the supply of Rituximab, a critical pharmaceutical product. The procurement specifically calls for two presentations of Rituximab: a 500 mg/50 ml solution for injection in a vial, and a 100 mg/10 ml solution for injection also in a vial. This acquisition is vital for the provision of essential medical treatments within the Chilean healthcare system.
The contracting authority is looking to establish a reliable supply chain for this high-demand biologic. Suppliers are expected to demonstrate their capacity to meet stringent quality standards, including adherence to Good Manufacturing Practices (GMP) and relevant pharmaceutical regulations in Chile. Bidders will likely need to provide comprehensive documentation regarding product origin, manufacturing processes, quality control measures, and product stability data. Furthermore, a robust logistical capability, ensuring timely and secure delivery across Chile, will be a key consideration. Experience in supplying similar pharmaceutical products to public health entities, particularly within Latin America, may be advantageous. The tender will evaluate proposals based on a combination of technical compliance, product quality, commercial terms, and the supplier's proven track record.
Data provenance
This notice is sourced from Chile Mercado Publico and was originally published on March 7, 2026. Last refreshed 26 days ago. Original language: Spanish. BidsFactory mirrors official procurement notices and links back to the source for full legal text.
Frequently asked questions about this tender
Where will the contract be performed?
The contract is for delivery in Chile. Foreign bidders should review local registration, taxation, and any in-country presence requirements before submitting.
How can I submit a bid?
Visit Chile Mercado Publico to access the full notice, required documents, and submission instructions provided by the contracting authority.
Is this tender still open?
No — the contract has already been awarded to SANDOZ CHILE SPA. The award notice is archived on BidsFactory for transparency and market intelligence.
What type of contract is this?
This is a Supplies contract in the Health & Medical sector. The classification helps bidders match the opportunity to their qualifications and registered scope of supply.
How much was the contract awarded for?
SANDOZ CHILE SPA was awarded the contract for CLP 257,991,840. The figure reflects the value disclosed by the contracting authority in the award notice.
Find tenders like this automatically
Set up alerts and filters that match your business — never miss a relevant opportunity again.